Business Standard

SPONSORED CONTENT

What's this ?

Sponsored Content is a "Paid For" Press Release distribution arrangement. Purely a Commercial Arrangement, brands and advertisers pay to be featured and to get this content published.

The Editorial/Content team at Business Standard has not contributed to writing/editing this article.

To get your brand featured in this Section write to assist@bsmail.in

Glenmark introduces NINDANIB (Nintedanib) and is amongst the first to launch the branded generic version at an affordable cost for the treatment of Pulmonary Fibrosis in India

ANI Press Release 

Tennis player James Blake
Glenmark Pharmaceuticals logo

Mumbai (Maharashtra) [India], October 14 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today launched NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India.

Glenmark being a leader in the area of respiratory has been amongst the first to launch the branded generic version at an affordable cost for the treatment of Pulmonary Fibrosis in India. This will provide patients a far more cost effective treatment option, and enable doctors to treat a wider patient population in the country.

Nintedanib is approved by the Indian drug regulator for the treatment of Idiopathic (unknown cause) Pulmonary Fibrosis (IPF).

Since IPF is a progressive disease that gets worse over time, starting treatment early and continuing treatment are important to slow disease progression. A lower monthly treatment cost therefore becomes crucial to ensure patients adhere to prescribed treatment in the long term.

So far Nintedanib has been studied extensively in various controlled clinical trials that have established its efficacy and safety. In a recently published INBUILDtm trial, Nintedanib showed significantly lower annual rate of decline in FVC (Forced Vital Capacity) - a measure of lung health - with various progressive fibrosing interstitial lung diseases4.

Moreover, two clinical trials are being rolled out for to study the efficacy and safety of Nintedanib as a treatment of SARS-COV2 induced pulmonary fibrosis in moderate to severe COVID-19 patients.

"With limited treatment options available, interstitial lung diseases pose a significant treatment challenge in India. The high price of newer treatments and the pill burden of existing options only add to poor patient adherence. By introducing NINDANIB, we hope to substantially reduce both the pill and cost burden for patients in India," said Alok Malik, Group Vice President & Business Head, India Formulations.

"Glenmark continues to invent and innovate healthcare solutions that meet specific and often hard-to-address needs of patients in India and the world," he added.

Pulmonary fibrosis (PF) is a respiratory condition characterized by the thickening and/or scarring of the lungs. This makes it difficult for oxygen to pass through the air sacs and into the bloodstream, causing symptoms such as shortness of breath and dry cough.

The average survival rate in patients with IPF is poor, with only 20 to 30 per cent of people surviving at least five years after diagnosis. The most frequent cause of death is respiratory failure. 2 IPF typically affects men over the age of 65 in India, and most people with IPF live only three to five years post diagnosis, if left untreated.

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, October 14 2020. 12:30 IST
RECOMMENDED FOR YOU

Glenmark introduces NINDANIB (Nintedanib) and is amongst the first to launch the branded generic version at an affordable cost for the treatment of Pulmonary Fibrosis in India

Mumbai (Maharashtra) [India], October 14 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today launched NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India.

Mumbai (Maharashtra) [India], October 14 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today launched NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India.

Glenmark being a leader in the area of respiratory has been amongst the first to launch the branded generic version at an affordable cost for the treatment of Pulmonary Fibrosis in India. This will provide patients a far more cost effective treatment option, and enable doctors to treat a wider patient population in the country.

Nintedanib is approved by the Indian drug regulator for the treatment of Idiopathic (unknown cause) Pulmonary Fibrosis (IPF).

Since IPF is a progressive disease that gets worse over time, starting treatment early and continuing treatment are important to slow disease progression. A lower monthly treatment cost therefore becomes crucial to ensure patients adhere to prescribed treatment in the long term.

So far Nintedanib has been studied extensively in various controlled clinical trials that have established its efficacy and safety. In a recently published INBUILDtm trial, Nintedanib showed significantly lower annual rate of decline in FVC (Forced Vital Capacity) - a measure of lung health - with various progressive fibrosing interstitial lung diseases4.

Moreover, two clinical trials are being rolled out for to study the efficacy and safety of Nintedanib as a treatment of SARS-COV2 induced pulmonary fibrosis in moderate to severe COVID-19 patients.

"With limited treatment options available, interstitial lung diseases pose a significant treatment challenge in India. The high price of newer treatments and the pill burden of existing options only add to poor patient adherence. By introducing NINDANIB, we hope to substantially reduce both the pill and cost burden for patients in India," said Alok Malik, Group Vice President & Business Head, India Formulations.

"Glenmark continues to invent and innovate healthcare solutions that meet specific and often hard-to-address needs of patients in India and the world," he added.

Pulmonary fibrosis (PF) is a respiratory condition characterized by the thickening and/or scarring of the lungs. This makes it difficult for oxygen to pass through the air sacs and into the bloodstream, causing symptoms such as shortness of breath and dry cough.

The average survival rate in patients with IPF is poor, with only 20 to 30 per cent of people surviving at least five years after diagnosis. The most frequent cause of death is respiratory failure. 2 IPF typically affects men over the age of 65 in India, and most people with IPF live only three to five years post diagnosis, if left untreated.

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
image
Business Standard
177 22

Glenmark introduces NINDANIB (Nintedanib) and is amongst the first to launch the branded generic version at an affordable cost for the treatment of Pulmonary Fibrosis in India

Mumbai (Maharashtra) [India], October 14 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today launched NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India.

Glenmark being a leader in the area of respiratory has been amongst the first to launch the branded generic version at an affordable cost for the treatment of Pulmonary Fibrosis in India. This will provide patients a far more cost effective treatment option, and enable doctors to treat a wider patient population in the country.

Nintedanib is approved by the Indian drug regulator for the treatment of Idiopathic (unknown cause) Pulmonary Fibrosis (IPF).

Since IPF is a progressive disease that gets worse over time, starting treatment early and continuing treatment are important to slow disease progression. A lower monthly treatment cost therefore becomes crucial to ensure patients adhere to prescribed treatment in the long term.

So far Nintedanib has been studied extensively in various controlled clinical trials that have established its efficacy and safety. In a recently published INBUILDtm trial, Nintedanib showed significantly lower annual rate of decline in FVC (Forced Vital Capacity) - a measure of lung health - with various progressive fibrosing interstitial lung diseases4.

Moreover, two clinical trials are being rolled out for to study the efficacy and safety of Nintedanib as a treatment of SARS-COV2 induced pulmonary fibrosis in moderate to severe COVID-19 patients.

"With limited treatment options available, interstitial lung diseases pose a significant treatment challenge in India. The high price of newer treatments and the pill burden of existing options only add to poor patient adherence. By introducing NINDANIB, we hope to substantially reduce both the pill and cost burden for patients in India," said Alok Malik, Group Vice President & Business Head, India Formulations.

"Glenmark continues to invent and innovate healthcare solutions that meet specific and often hard-to-address needs of patients in India and the world," he added.

Pulmonary fibrosis (PF) is a respiratory condition characterized by the thickening and/or scarring of the lungs. This makes it difficult for oxygen to pass through the air sacs and into the bloodstream, causing symptoms such as shortness of breath and dry cough.

The average survival rate in patients with IPF is poor, with only 20 to 30 per cent of people surviving at least five years after diagnosis. The most frequent cause of death is respiratory failure. 2 IPF typically affects men over the age of 65 in India, and most people with IPF live only three to five years post diagnosis, if left untreated.

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22